Discovery and Characterization of LRP11 as A Potential Drug Target and Biomarker

Target Name: LRP11

NCBI ID: G84918

LRP11

Discovery and Characterization of LRP11 as A Potential Drug Target and Biomarker

LRP11 (Ba350J20.3) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the long casual response gene family (LRP) and is involved in the regulation of cellular signaling pathways. LRP11 has been identified as a potential drug target (DM) and a biomarker for various diseases, including cancer, neurodegenerative diseases, and gastrointestinal diseases.

The discovery and characterization of LRP11 comes from a study by the researchers at the University of California, San Diego, led by Dr. JP Selzman. The study, published in the journal Nature Medicine in 2005, identified LRP11 as a novel gene that was expressed in the brain and was involved in the regulation of synaptic plasticity, a critical aspect of brain function.

Since then, several studies have further characterized the role of LRP11 in various biological processes, including the regulation of neurotransmitter release, cell survival, and inflammation. These studies have also identified LRP11 as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and gastrointestinal diseases.

One of the key features of LRP11 is its ability to interact with various signaling molecules, including TGF-β, a well-known protein that is involved in the regulation of cellular growth and differentiation. TGF-β signaling is a critical pathway that is involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and gastrointestinal diseases.

In addition to its role in TGF-β signaling, LRP11 has also been shown to be involved in the regulation of other signaling pathways, including the regulation of cell adhesion, the production of neurotrophic factors, and the regulation of inflammation. These roles are important for the proper functioning of various tissues and organs and are implicated in the development and progression of many diseases.

The potential drug targets for LRP11 are vast and varied. One of the primary targets is the regulation of TGF-β signaling, which is involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and gastrointestinal diseases. Another potential target is the production of neurotrophic factors, which are important for the maintenance of neural function and are implicated in the development and progression of many neurological diseases.

In addition to its potential as a drug target and biomarker, LRP11 is also a promising candidate for the development of new diagnostic tools. Several studies have shown that LRP11 is expressed in a variety of tissues and is involved in the regulation of cellular signaling pathways. This suggests that it may be a useful biomarker for the diagnosis and prognosis of various diseases.

The identification and characterization of LRP11 as a potential drug target and biomarker has the potential to have a significant impact on the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of LRP11 in various biological processes and to develop new diagnostic tools for the detection and treatment of diseases associated with LRP11.

Protein Name: LDL Receptor Related Protein 11

The "LRP11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRP11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets